Market Closed -
Nasdaq
04:00:00 2024-06-03 pm EDT
|
5-day change
|
1st Jan Change
|
11.76
USD
|
+21.49%
|
|
+29.80%
|
-16.18%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,840
|
372
|
98.27
|
766.3
|
657.3
|
-
|
-
|
Enterprise Value (EV)
1 |
1,840
|
372
|
98.27
|
766.3
|
575.1
|
528.6
|
540
|
P/E ratio
|
-14.1
x
|
-5.2
x
|
-0.94
x
|
-6.56
x
|
-4.89
x
|
-4.51
x
|
-4.24
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
113
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
92.5
x
|
EV / EBITDA
|
-85.5
x
|
-5.22
x
|
-0.92
x
|
-7.33
x
|
-4.27
x
|
-3.03
x
|
-2.5
x
|
EV / FCF
|
-92.4
x
|
-7.12
x
|
-1.19
x
|
-9.15
x
|
-7.16
x
|
-3.94
x
|
-3.6
x
|
FCF Yield
|
-1.08%
|
-14%
|
-83.9%
|
-10.9%
|
-14%
|
-25.4%
|
-27.8%
|
Price to Book
|
-
|
-
|
0.5
x
|
3.04
x
|
2.77
x
|
2.09
x
|
-
|
Nbr of stocks (in thousands)
|
38,274
|
39,745
|
40,110
|
54,622
|
55,893
|
-
|
-
|
Reference price
2 |
48.08
|
9.360
|
2.450
|
14.03
|
11.76
|
11.76
|
11.76
|
Announcement Date
|
3/17/21
|
2/28/22
|
3/9/23
|
3/11/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
5.836
|
EBITDA
1 |
-
|
-21.52
|
-71.33
|
-106.6
|
-104.6
|
-134.8
|
-174.2
|
-216.2
|
EBIT
1 |
-
|
-21.53
|
-71.49
|
-107
|
-105
|
-138.1
|
-167.2
|
-188.7
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,233.83%
|
Earnings before Tax (EBT)
1 |
-
|
-22.12
|
-71.1
|
-104.8
|
-96.66
|
-134
|
-165.6
|
-183.8
|
Net income
1 |
-4.316
|
-23.99
|
-71.1
|
-104.8
|
-96.66
|
-134
|
-165.6
|
-183.8
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,148.65%
|
EPS
2 |
-0.6000
|
-3.420
|
-1.800
|
-2.620
|
-2.140
|
-2.407
|
-2.606
|
-2.773
|
Free Cash Flow
1 |
-
|
-19.92
|
-52.26
|
-82.43
|
-83.73
|
-80.33
|
-134
|
-150
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,570.25%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/30/20
|
3/17/21
|
2/28/22
|
3/9/23
|
3/11/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-21.68
|
-23.17
|
-33.21
|
-23.13
|
-27.12
|
-29.5
|
-21.5
|
-23.25
|
-30.33
|
-34.25
|
-33.98
|
-35.87
|
-39.31
|
-
|
-
|
EBIT
1 |
-21.76
|
-23.25
|
-33.29
|
-23.22
|
-27.22
|
-29.6
|
-21.6
|
-23.34
|
-30.42
|
-34.34
|
-33.32
|
-34.59
|
-36.46
|
-34.14
|
-38
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-21.64
|
-23.03
|
-32.86
|
-22.72
|
-26.18
|
-28.29
|
-20.1
|
-21.5
|
-26.77
|
-30.97
|
-32.81
|
-33.98
|
-36.28
|
-35
|
-38
|
Net income
1 |
-21.64
|
-23.03
|
-32.86
|
-22.72
|
-26.18
|
-28.29
|
-20.1
|
-21.5
|
-26.77
|
-30.97
|
-32.81
|
-33.98
|
-36.28
|
-35
|
-38
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.5400
|
-0.5800
|
-0.8200
|
-0.5700
|
-0.6500
|
-0.7000
|
-0.4900
|
-0.4800
|
-0.4900
|
-0.5600
|
-0.5854
|
-0.6060
|
-0.6498
|
-0.6000
|
-0.6500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/22
|
5/9/22
|
8/9/22
|
11/8/22
|
3/9/23
|
5/9/23
|
8/8/23
|
11/7/23
|
3/11/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
82.2
|
129
|
117
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-19.9
|
-52.3
|
-82.4
|
-83.7
|
-80.3
|
-134
|
-150
|
ROE (net income / shareholders' equity)
|
-
|
-14.6%
|
-22.8%
|
-43.5%
|
-42.8%
|
-63.8%
|
-78.7%
|
-73.6%
|
ROA (Net income/ Total Assets)
|
-
|
-14%
|
-22.3%
|
-41%
|
-39.2%
|
-49.2%
|
-48.2%
|
-
|
Assets
1 |
-
|
171.4
|
319.3
|
255.8
|
246.3
|
272.5
|
343.3
|
-
|
Book Value Per Share
2 |
-
|
-
|
-
|
4.900
|
4.620
|
4.250
|
5.620
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-2.050
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.06
|
1.58
|
0.36
|
-
|
1
|
1.33
|
2
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
34.27%
|
Announcement Date
|
10/30/20
|
3/17/21
|
2/28/22
|
3/9/23
|
3/11/24
|
-
|
-
|
-
|
Last Close Price
11.76
USD Average target price
26.88
USD Spread / Average Target +128.53% Consensus |
1st Jan change
|
Capi.
|
---|
| -16.18% | 541M | | +48.64% | 54.63B | | -6.44% | 39.92B | | +37.07% | 38.82B | | +14.28% | 26.86B | | -11.17% | 26.22B | | -21.40% | 18.78B | | +25.64% | 12.21B | | +0.96% | 12.16B | | +27.04% | 11.94B |
Other Biotechnology & Medical Research
|